The U.S. Food and Drug Administration has reminded more than 2,200 medical product companies and researchers of the requirements to submit certain clinical trial results information to ClinicalTrials.gov.
Companies and researchers often fail to disclose negative trial results, resulting in significant gaps in the public record and a publication bias that obscures the true landscape of drug development outcomes—overrepresenting successes and underrepresenting failures. This gap can also create a distorted perception of the safety and efficacy of medical products.
According to an internal analysis, 29.6% of studies that are highly likely to fall under mandatory reporting requirements have no results information submitted to ClinicalTrials.gov. Studies subject to the mandatory reporting requirements include interventional studies with a U.S.
nexus and an FDA-regulated product that are past the deadline to report; it excludes Phase 1 and device feasibility studies. "Far too often, companies are suppressing unfavorable clinical trial results and keeping them secret from patients and the scientific community.
The agency highlights that withholding negative results creates gaps in the public record and can bias perceptions of the safety and efficacy of medical products.
It draws attention to mandatory reporting dynamics and the ethical implications of non-disclosure.
nexus and involve an FDA-regulated product, and which are past reporting deadlines.
Phase 1 and device feasibility studies are excluded from the described mandatory reporting requirements.
The agency frames this as an invitation to voluntary compliance, with the possibility of formal risk-based actions if noncompliance persists.
The FDA treats this as meaningful noncompliance that contributes to publication bias and uncertainty about product safety and effectiveness.
The message underscores that clinicians and researchers deserve access to comprehensive data to inform prescribing decisions and scientific interpretation.
She describes the messages as a mechanism to improve public access to study findings and to enhance patient safety through better information on benefits and risks.
The agency signals that such notices are a procedural step in its ongoing compliance oversight.
It also does not specify which studies or sponsors are now in process of resolution, nor does it quantify subsequent outcomes of the outreach.
The FDA presents timely communication as part of a broader public-health mission, aiming to reduce information gaps that can influence risk-benefit assessments.
It also does not report any immediate corrections or adherence results following the March 2026 notices.